ATARA BIOTHERAPEUTICS, INC. Financing Cash Flow
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Financing Cash Flow of $7.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.83M, a 68.47% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.95M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$3.00K.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.05M, a 97.07% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $16.10M, a 72.85% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $59.28M, a 2849.35% increase from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $2.01M, a 96.21% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $53.08M, a 48.93% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $7.78M 10-Q · filed 2026-08-12 | $7.77M derived: sum of 3 quarters · filed 2026-08-12 | $8.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.95M 10-Q · filed 2026-05-12 | $2.95M derived: sum of 2 quarters · filed 2026-05-12 | $4.00M derived: sum of 3 quarters · filed 2026-05-12 | $19.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.04M derived: sum of 2 quarters · filed 2026-03-16 | $16.35M derived: sum of 3 quarters · filed 2026-08-12 | $16.10M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.35M derived: sum of 2 quarters · filed 2026-08-12 | $16.10M 10-Q · filed 2025-11-12 | $15.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $15.05M 10-Q · filed 2026-08-12 | $14.73M derived: sum of 3 quarters · filed 2026-08-12 | $50.52M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$250.00K 10-Q · filed 2026-05-12 | -$578.00K derived: sum of 2 quarters · filed 2026-05-12 | $35.22M derived: sum of 3 quarters · filed 2026-05-12 | $34.89M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $35.47M derived: sum of 2 quarters · filed 2026-03-16 | $35.14M derived: sum of 3 quarters · filed 2026-03-16 | $59.28M 10-K · filed 2026-03-16 |
| 2024-09-30 | $35.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $35.47M derived: sum of 2 quarters · filed 2025-11-12 | $59.61M 10-Q · filed 2025-11-12 | $61.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $23.82M 10-Q · filed 2025-08-11 | $25.33M derived: sum of 3 quarters · filed 2025-08-11 | $25.12M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $24.14M 10-Q · filed 2025-05-15 | $25.65M derived: sum of 2 quarters · filed 2025-05-15 | $25.45M derived: sum of 3 quarters · filed 2025-05-15 | $25.92M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.30M derived: sum of 2 quarters · filed 2025-03-07 | $1.77M derived: sum of 3 quarters · filed 2025-03-07 | $2.01M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $263.00K derived: sum of 2 quarters · filed 2024-11-12 | $498.00K 10-Q · filed 2024-11-12 | $32.79M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $706.00K 10-Q · filed 2024-08-12 | $33.00M derived: sum of 3 quarters · filed 2024-08-12 | $32.78M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $235.00K 10-Q · filed 2024-05-09 | $32.52M derived: sum of 2 quarters · filed 2024-05-09 | $32.31M derived: sum of 3 quarters · filed 2024-05-09 | $33.47M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $32.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $32.08M derived: sum of 2 quarters · filed 2024-03-28 | $33.23M derived: sum of 3 quarters · filed 2024-03-28 | $53.08M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $943.00K derived: sum of 2 quarters · filed 2023-11-01 | $20.79M 10-Q · filed 2023-11-01 | $72.26M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $21.01M 10-Q · filed 2023-08-08 | $72.48M derived: sum of 3 quarters · filed 2023-08-08 | $119.61M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $19.85M 10-Q · filed 2023-05-08 | $71.32M derived: sum of 2 quarters · filed 2023-05-08 | $118.46M derived: sum of 3 quarters · filed 2023-05-08 | $120.90M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $51.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $98.61M derived: sum of 2 quarters · filed 2023-02-08 | $101.05M derived: sum of 3 quarters · filed 2023-02-08 | $103.94M 10-K · filed 2023-02-08 |
| 2021-09-30 | $47.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $49.58M derived: sum of 2 quarters · filed 2022-11-08 | $52.48M 10-Q · filed 2022-11-08 | $231.27M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $5.34M 10-Q · filed 2022-08-08 | $184.13M derived: sum of 3 quarters · filed 2023-02-08 | $217.64M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | $2.89M 10-Q · filed 2022-05-05 | $181.69M derived: sum of 2 quarters · filed 2023-02-08 | $215.19M derived: sum of 3 quarters · filed 2023-02-08 | $406.51M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | $178.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $212.30M derived: sum of 2 quarters · filed 2023-02-08 | $403.62M derived: sum of 3 quarters · filed 2023-02-08 | $427.57M 10-K · filed 2023-02-08 |
| 2020-09-30 | $33.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $224.82M derived: sum of 2 quarters · filed 2021-11-04 | $248.78M 10-Q · filed 2021-11-04 | $286.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $191.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $215.27M 10-Q · filed 2021-08-09 | $252.72M derived: sum of 3 quarters · filed 2022-02-28 | $398.66M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $23.96M 10-Q · filed 2021-05-04 | $61.41M derived: sum of 2 quarters · filed 2022-02-28 | $207.34M derived: sum of 3 quarters · filed 2022-02-28 | $214.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $37.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $183.38M derived: sum of 2 quarters · filed 2022-02-28 | $190.71M derived: sum of 3 quarters · filed 2022-02-28 | $188.79M 10-K · filed 2022-02-28 |
| 2019-09-30 | $145.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $153.26M derived: sum of 2 quarters · filed 2020-11-09 | $151.34M 10-Q · filed 2020-11-09 | $157.36M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $5.40M 10-Q · filed 2020-08-05 | $11.42M derived: sum of 3 quarters · filed 2021-03-01 | $10.91M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$1.93M 10-Q · filed 2020-05-06 | $4.09M derived: sum of 2 quarters · filed 2021-03-01 | $3.58M derived: sum of 3 quarters · filed 2021-03-01 | $59.60M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.51M derived: sum of 2 quarters · filed 2021-03-01 | $61.52M derived: sum of 3 quarters · filed 2021-03-01 | $357.54M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$515.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $55.50M derived: sum of 2 quarters · filed 2019-11-07 | $351.51M 10-Q · filed 2019-11-07 | $352.21M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $56.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $352.03M 10-Q · filed 2019-08-08 | $352.73M derived: sum of 3 quarters · filed 2020-02-27 | $362.60M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $296.01M 10-Q · filed 2019-05-09 | $296.71M derived: sum of 2 quarters · filed 2020-02-27 | $306.58M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $10.57M derived: sum of 2 quarters · filed 2020-02-27 | $20.05M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $9.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $19.35M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $9.48M 10-Q · filed 2018-08-01 | |||
| 2016-12-31 | $506.00K 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |